explore -WSS

explore

author：fashion 2025-08-20 09:41:32 - browse：68

Cathy McMorris Rodgers -- health policy coverage from STAT — Rep. Cathy McMorris Rodgers announced her plans to leave Congress at the end of 2024. Anna Moneymaker/Getty Images

WASHINGTON — Rep. Cathy McMorris Rodgers, the chair of a crucial House committee that handles health care issues, plans to leave Congress at the end of the year, she announced Thursday.

It will be a major shakeup for a panel already ravaged by Republican retirements. Reps. Michael Burgess (R-Texas), Larry Bucshon (R-Ind.), Jeff Duncan (R-S.C.), Debbie Lesko (R-Ariz.), Greg Pence (R-Ind.) and Kelly Armstrong (R-N.D.) are all leaving at the end of this Congress, too.

Under McMorris Rodgers, the panel led the way for House passage of a health care price transparency package that included the first major proposal to equalize payment between hospital outpatient departments and physician offices.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Warren pushes Witty on UnitedHealth's control over physicians

WSS

Warren pushes Witty on UnitedHealth's control over physicians

Warren pushes Witty on UnitedHealth's control over physicians

Study gives hint on South Asians’ higher risk of cardiovascular disease

Congress might make insulin pumps more accessible to the blind

Chemotherapy before breast cancer surgery might fuel metastasis

Class action alleges UnitedHealth concealed DOJ probe

knowledge

explore

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Chemotherapy before breast cancer surgery might fuel metastasis

What does generative AI mean for health care? We asked experts

As billionaires fund anti

The cancer drug shortage isn’t new — and neither are the solutions

Congress might make insulin pumps more accessible to the blind

Novavax promises a turnaround & Lilly roils the obesity market

AltruBio raises $225 million to develop ulcerative colitis drug

FDA approval of Sarepta Duchenne genetic therapy gives me hope

STAT Boddities: What happens to the brain when we get scared?

explore

AltruBio raises $225 million to develop ulcerative colitis drug

Websites selling Wegovy, Zepbound ingredients targeted by FDA

BIO to announce reorganization, senior leaders expected to depart

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Welsh Carson private equity firm escapes from FTC antitrust case

Juul documents reveal insider tactics on political lobbying

Wikipedia

leisure time

entertainment

hotspot